Literature DB >> 1379801

Hammerhead ribozyme cleavage of hamster prion pre-mRNA in complex cell-free model systems.

R B Denman1, B Purow, R Rubenstein, D L Miller.   

Abstract

The cleavage properties of a trans-acting hammerhead ribozyme targeted 51 bases upstream of the putative splicing branch point in the hamster prion pre-mRNA intron were investigated in cell-free model systems in vitro. The specificity of cleavage was demonstrated by the inability of this ribozyme to cleave a non-homologous synthetic message encoding part of the beta amyloid peptide precursor, beta APP, and by the inability of the prion pre-mRNA to be cleaved by a ribozyme targeted to beta amyloid peptide precursor mRNA. Also, the addition of total RNA isolated from rat brain had only a minimal effect on the cleavage of the prion substrate pre-mRNA by the ribozyme. Finally neither the presence of 100 ng of nuclear or cytoplasmic proteins were found to affect the rate of cleavage in vitro.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1379801     DOI: 10.1016/0006-291x(92)90870-q

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

Review 1.  Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects.

Authors:  R A Stull; F C Szoka
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

2.  Ribozyme mediated degradation of beta-amyloid peptide precursor mRNA in COS-7 cells.

Authors:  R B Denman; M Smedman; W Ju; R Rubenstein; A Potempska; D L Miller
Journal:  Nucleic Acids Res       Date:  1994-06-25       Impact factor: 16.971

3.  Cleavage of full-length beta APP mRNA by hammerhead ribozymes.

Authors:  R B Denman
Journal:  Nucleic Acids Res       Date:  1993-08-25       Impact factor: 16.971

4.  Pharmaceutical marketing strategies' influence on physicians' prescribing pattern in Lebanon: ethics, gifts, and samples.

Authors:  Micheline Khazzaka
Journal:  BMC Health Serv Res       Date:  2019-01-30       Impact factor: 2.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.